London Daily

Focus on the big picture.
Friday, Jul 04, 2025

City analysts come out in support of Glaxo plan

City analysts come out in support of Glaxo plan

Brokers say shares are undervalued compared with New GSK prospects

A growing number of City analysts have come out in support of GlaxoSmithKline’s restructuring plan under chief executive Emma Walmsley despite the efforts of activist investor Elliott to stir up shareholders.

Brokers Morgan Stanley, Liberum, Jefferies and Berenberg issued research notes broadly supportive of the strategy which will split off the consumer arm and focus “new” GSK on its pharmaceuticals and vaccines operations.

All said the current bombed-out share price did not reflect the true value of the business post-restructuring.

However, they stressed that GSK had to build up investors’ confidence in the strength of its pipeline of drugs in development. Key to this will be its June 23 investor day when Walmsley’s team will give more details on prospects for New GSK in the first five years of its life.

Berenberg said patent expiries meant GSK needed to get two “megabuster” new drugs to market by the middle of the decade.

Morgan Stanley said the new five-year targets expected at the event could trigger upgrades to the City’s profit forecasts but warned increased disclosure on the progress in its pipeline was needed.

Several were expecting a dividend cut to fund investment in research and development. Liberum speculated a “part-IPO” might be signalled for the consumer division.

What the analysts said:


Morgan Stanley


Price target 1550p


“We believe the that the new five year targets [unveiled on 23 June] could provide upside to consensus earnings in 2026, but incremental progress in innovation and limited long-term visibility suggest GSK could remain a “show-me” story.”

Points out that the biopharma arm is becoming a more innovation-led business, but largely because established medicines are in decline and some HIV drugs come off patent in 2027-29.

Says the 23 June meeting will focus on four areas:

1) Reprioritising established products

2) Details on how it will grow its ViiV HIV business around its Cabotegravir product

3) Putting into context how innovations in mRNA, highlighted by the Covid crisis, will disrupt GSK’s vaccines business

4) Focusing investors’ minds on six pivotal programmes in its pharmaceuticals R&D pipeline

Liberum


Price target 1700p


Suggests the capital markets event will outline forecast sales growth of “new GSK” at 6% with underlying profit growth at 10% a year for 2021-26. Both of those are slightly ahead of City forecasts.

Expects clarification on how Walmsley plans to split off the consumer arm. Debate is raging around whether it should be through an IPO or a spin-off. Some shareholders are concerned an IPO would be used to raise new money, meaning existing investors get diluted. Liberum argues a “part-IPO” looked increasingly likely.

“We continue to believe the long-term potential of New GSK is underappreciated and reiterate our BUY rating and £17 target price.

Berenberg


Price target 1570p


Expects news on growth outlook for New GSK for the next five or 10 years and on the extent of the proposed 2022 dividend cut - needed to fund R&D spend.

“Clear communication from management will be critical in order to convince many sceptical yet intrigued investors that now is the time to buy.

“We continue to believe there is deep value and view the implied negative pipeline value for GSK as unwarranted; we reiterate our Buy recommendation.”

Looking at how the management’s own performance pay is set, Berenberg predicts five year sales forecasts out to 2026 will be 5% annual growth with operating profit 10% - the latter being higher than the consensus of 8% in the City.

Says that to make up for the patent expiry at the end of 2017 of dolutegravir, an HIV/AIDS retroviral, GSK needs two “megabusters”, indications of which will require 8-10 “shots on goal” in the pipeline. Berenberg has identified “at least four” in phase II or III trials that fit the bill.

The broker assumes a 50% cut in the dividend to pay to bring in new blockbusters.

Jefferies:


Price target 1925p


Predicts dividend will be halved, broadly as expected, but thinks New GSK’s five year growth plan could be bolder than the market has factored in, with bigger sales and profit expectations.

Says a spin-off of the consumer arm is more likely than an IPO. A flotation and fundraiser would put people off holding GSK shares for a year, it says.

Key is to build belief in the pipeline, namely, in its core areas of vaccines, oncology, immunology and infectious diseases including HIV.

Says GSK could raise cash to reinvest in the business by selling off some of the pharma portfolio such as dermatology.

Highlights that its investments in biotech stakes including Vir, CureVac and 23andMe, which is floating soon, are underappreciated.

Newsletter

Related Articles

0:00
0:00
Close
DJI Launches Heavy-Duty Coaxial Quadcopter with 80 kg Lift Capacity
U.S. Senate Approves Major Legislation Dubbed the 'Big Beautiful Bill'
Largest Healthcare Fraud Takedown in U.S. History Announced by DOJ
Poland Implements Border Checks Amid Growing Migration Tensions
Political Dispute Escalates Between Trump and Musk
Emirates Airline Expands Market Share with New $20 Million Campaign
Amazon Reaches Milestone with Deployment of One Millionth Robot
US Senate Votes to Remove AI Regulation Moratorium from Domestic Policy Bill
Yulia Putintseva Calls for Spectator Ejection at Wimbledon Over Safety Concerns
Jury Deliberations in Diddy Trial Yield Partial Verdict in Serious Criminal Charges
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
King Charles Plans Significant Role for Prince Harry in Coronation
Two Chinese Nationals Arrested for Espionage Activities Against U.S. Navy
Amazon Reaches Major Automation Milestone with Over One Million Robots
Extreme Heat Wave Sweeps Across Europe, Hitting Record Temperatures
Meta Announces Formation of Ambitious AI Unit, Meta Superintelligence Labs
Robots Compete in Football Tournament in China Amid Injuries
Trump Administration Considers Withdrawal of Funding for Hospitals Providing Gender Treatment to Minors
Texas Enacts Law Allowing Gold and Silver Transactions
China Unveils Miniature Insect-Like Surveillance Drone
OpenAI Secures Multimillion-Dollar AI Contracts with Pentagon, India, and Grab
Marc Marquez Claims Victory at Dutch Grand Prix Amidst Family Misfortune
Germany Votes to Suspend Family Reunification for Asylum Seekers
Elon Musk Critiques Senate Budget Proposal Over Job Losses and Strategic Risks
Los Angeles Riots ended with Federal Investigations into Funding
Budapest Pride Parade Draws 200,000 Participants Amid Government Ban
Southern Europe Experiences Extreme Heat
Xiaomi's YU7 SUV Launch Garners Record Pre-Orders Amid Market Challenges
Jeff Bezos and Lauren Sanchez's Lavish Wedding in Venice
Russia Launches Largest Air Assault on Ukraine Since Invasion
Education Secretary Announces Overhaul of Complaints System Amid Rising Parental Grievances
Massive Anti-Government Protests Erupt in Belgrade
Trump Ends Trade Talks with Canada Over Digital Services Tax
UK Government Softens Welfare Reform Plans Amid Labour Party Rebellion
Labour Faces Rebellion Over Disability Benefit Reforms Ahead of Key Vote
Jeff Bezos and Lauren Sánchez Host Lavish Wedding in Venice Amid Protests
Trump Asserts Readiness for Further Strikes on Iran Amid Nuclear Tensions
North Korea to Open New Beach Resort to Boost Tourism Economy
UK Labour Party Faces Internal Tensions Over Welfare Reforms
Andrew Cuomo Hints at Potential November Comeback Amid Democratic Primary Results
Curtis Sliwa Champions His Vision for New York City Amid Rising Crime Concerns
Federal Reserve Proposes Changes to Capital Rule Affecting Major Banks
EU TO HUNGARY: LET THEM PRIDE OR PREP FOR SHADE. ORBÁN TO EU: STAY IN YOUR LANE AND FIX YOUR OWN MESS.
Trump Escalates Criticism of Media Over Iran Strike Coverage
Trump Announces Upcoming US-Iran Meeting Amid Controversial Airstrikes
Trump Moves to Reshape Middle East Following Israel-Iran Conflict
Big Four Accounting Firms Fined in Exam Cheating Scandal
NATO Members Agree to 5% Defense Spending Target by 2035
Australia's Star Casino Secures $195 Million Rescue Package Amid Challenges
UK to Enhance Nuclear Capabilities with Acquisition of F-35A Fighter Jets
×